Health IT Vendor Allscripts Changes Corporate Name to Veradigm
After two years of streamlining its corporate portfolio, all remaining assets of health IT vendor Allscripts are now part of the Veradigm Network.
Health IT vendor Allscripts announced that effective January 1, 2023, it has changed its name to VeradigmInc.
Allscripts had been transitioning its solutions to the Veradigm brand during 2022 and will now formally be known as Veradigm.
Veradigm connects over 300,000 healthcare providers via the Veradigm Network, representing data for over 170 million patients.
“As our markets continue to evolve, completing our brand transition to Veradigm represents a capstone on our own evolution as a company,” Rick Poulton, Veradigm’s chief executive officer, said in a public statement. “We are well-positioned to drive growth and serve each market where we compete.”
After more than two years of streamlining its corporate portfolio, all remaining Allscripts assets, including EHRs, practice management systems, and patient communication platforms, are now part of the Veradigm Network.
The vendor’s recent business ventures have focused on advancing interoperability. Veradigm recently partnered with the Social Security Administration (SSA) to support EHR interoperability for disability claims. By allowing SSA to electronically request and receive EHR data through the vendor’s network solution, the health IT can minimize clinician burden related to EHR data exchange.
Veradigm also recently partnered with health IT vendor PRA Health Sciences to create an EHR-based clinical research network that extends the clinical trial process into EHR workflows.
The network aims to streamline the clinical trial recruitment process by integrating clinical research as a care option (CRAACO) into the EHRs of 40 million patients.
Representatives said the benefits of the network are two-fold; patients have greater access to CRAACO, leading to more diverse clinical trial participation.
The network also aims to aid clinical trial sites and sponsors by simplifying two of the most lengthy and costly clinical trial stages: data management and monitoring.